Xiaoping Ning
Thomas Jefferson University
Quality of lifeInternal medicineCalcitonin gene-related peptideRandomized controlled trialPhysical therapyAdverse effectPlaceboDosingTolerabilityMigraineDiscontinuationChronic MigraineIn patientEpisodic migraineClinical trialMedicine
13Publications
3H-index
109Citations
Publications 18
Newest
Recently, Gao et al. published an article titled "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials" which concluded that monthly administration of fremanezumab led to significant reduction in monthly migraine days (MMD) when compared to quarterly fremanezumab. We have noted a critical flaw in Gao et al. meta-analysis wherein the authors have mistakenly utilized standard error values in place of standard de...
Source
#2Xiaoping NingH-Index: 3
Last. Dawn C. Buse (Albert Einstein College of Medicine)H-Index: 53
view all 6 authors...
Background null Migraine is associated with depression as well as negative impact on quality of life and work productivity. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. null Objective null In this open-label extension (OLE) of the phase 3b FOCUS study, we assessed patient-reported outcomes (PROs) over time. null Methods null Patients with episodic migraine (E...
Source
#1Messoud Ashina (UCPH: University of Copenhagen)H-Index: 65
#2Joshua M. CohenH-Index: 8
Last. Hans-Christoph Diener (University of Duisburg-Essen)H-Index: 132
view all 9 authors...
BACKGROUND Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. In this study, we evaluated the long-term efficacy, safety, and tolerability of monthly and quarterly fremanezumab. METHODS Episodic migraine and chronic migraine patients completing the 12-week double-blind period of the FOCUS trial entered the 12-week open-label extension and received 3 monthly doses of...
Source
#1Orit Cohen-BarakH-Index: 8
Last. Laura Rabinovich-GuilattH-Index: 4
view all 15 authors...
BackgroundPotential fremanezumab doses for pediatric patients were evaluated using pharmacokinetic modeling and simulation. An open-label phase 1 pharmacokinetic and safety study was conducted in p...
Source
#2Joshua M. CohenH-Index: 8
Last. Patricia Pozo-Rosich (Autonomous University of Barcelona)H-Index: 22
view all 6 authors...
ObjectiveTo evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migra...
Source
#1Yoel KesslerH-Index: 1
#2Xiaoping NingH-Index: 3
Last. Joshua M. CohenH-Index: 8
view all 3 authors...
Source
#2Mikko Kärppä (OUH: Oulu University Hospital)H-Index: 15
Last. Uwe Reuter (Charité)H-Index: 42
view all 7 authors...
BACKGROUND The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated efficacy by country in the FOCUS study of fremanezumab in adults with episodic migraine or chronic migraine and documented inadequate response to 2 to 4 migraine preventive medication classes. METHODS Overall, 838 participants were enrolled in t...
Source
#1Joshua M. CohenH-Index: 8
#2Xiaoping NingH-Index: 3
Last. Jennifer StrattonH-Index: 1
view all 9 authors...
BACKGROUND Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical trials along with favorable safety and tolerability profiles. Although erenumab is a human mAb and the others have been humanized to varying degrees, they all have the capacity to provoke immune reactions. The present review article aims to discuss the curre...
Source
#1Peter J. Goadsby ('KCL': King's College London)H-Index: 137
Last. David W. Dodick ('KCL': King's College London)H-Index: 94
view all 7 authors...
Objective To assess the long-term safety, tolerability, and efficacy of fremanezumab, a fully humanized monoclonal antibody approved for the preventive treatment of migraine. Methods A 52-week, multicenter, randomized, double-blind, parallel-group study evaluated fremanezumab monthly or quarterly in adults with chronic migraine (CM) or episodic migraine (EM). Safety and tolerability were assessed by adverse event (AE) monitoring (performed by the investigators), systematic local injection-site a...
Source
#1Stephanie J. Nahas (Thomas Jefferson University)H-Index: 7
#2Yoel KesslerH-Index: 1
Last. Stephen D. Silberstein (Thomas Jefferson University)H-Index: 109
view all 7 authors...
Objective: To evaluate the cardiovascular safety of fremanezumab in patients with episodic migraine (EM) and chronic migraine (CM). Background: Understanding the cardiovascular safety of medications targeting the calcitonin gene-related peptide (CGRP) pathway is critically important given the vasodilatory properties of CGRP. Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets CGRP, has been studied in three phase 3 trials. Design/Methods: This analysis of the ca...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.